Ageing with HIV: medication use and risk for potential drug-drug interactions

J Antimicrob Chemother. 2011 Sep;66(9):2107-11. doi: 10.1093/jac/dkr248. Epub 2011 Jun 16.

Abstract

Objectives: To compare the use of co-medication, the potential drug-drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥ 50 years or <50 years.

Methods: All ART-treated participants were prospectively included once during a follow-up visit of the Swiss HIV Cohort Study. Information on any current medication was obtained by participant self-report and medical prescription history. The complete treatment was subsequently screened for PDDIs using a customized version of the Liverpool drug interaction database.

Results: Drug prescriptions were analysed for 1497 HIV-infected individuals: 477 age ≥ 50 and 1020 age <50. Older patients were more likely to receive one or more co-medications compared with younger patients (82% versus 61%; P < 0.001) and thus had more frequent PDDIs (51% versus 35%; P < 0.001). Furthermore, older patients tended to use a higher number of co-medications and certain therapeutic drug classes more often, such as cardiovascular drugs (53% versus 19%; P < 0.001), gastrointestinal medications (10% versus 6%; P = 0.004) and hormonal agents (6% versus 3%; P = 0.04). PDDIs with ART occurred mainly with cardiovascular drugs (27%), CNS agents (22%) and methadone (6%) in older patients and with CNS agents (27%), methadone (15%) and cardiovascular drugs (11%) in younger patients. The response to ART did not differ between the two groups.

Conclusions: The risk for PDDIs with ART increased in older patients who take more drugs than their younger HIV-infected counterparts. However, medication use in older and younger patients did not differ in terms of effect on antiretroviral tolerability and response.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aging / physiology*
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use
  • Central Nervous System Agents / adverse effects
  • Central Nervous System Agents / therapeutic use
  • Cohort Studies
  • Drug Interactions
  • Drug Prescriptions / statistics & numerical data
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Hormones / adverse effects
  • Hormones / therapeutic use
  • Humans
  • Male
  • Methadone / adverse effects
  • Methadone / therapeutic use
  • Middle Aged
  • Narcotics / adverse effects
  • Narcotics / therapeutic use
  • Socioeconomic Factors
  • Substance Abuse, Intravenous / complications
  • Substance-Related Disorders / complications
  • Switzerland / epidemiology

Substances

  • Anti-HIV Agents
  • Cardiovascular Agents
  • Central Nervous System Agents
  • Gastrointestinal Agents
  • Hormones
  • Narcotics
  • Methadone